soul trial oral semaglutide cardiovascular outcomes 2024 results nejm

soul trial oral semaglutide cardiovascular outcomes 2024 results nejm found to lower risk of heart failure events in people with type 2 diabetes SOUL: Oral Semaglutide Bests Usual

Name: soul trial oral semaglutide cardiovascular outcomes 2024 results nejm found to lower risk of heart failure events in people with type 2 diabetes SOUL: Oral Semaglutide Bests Usual
Brand: franialexport.com
SKU: 85407549658
Price: 20.16 USD
Availability: InStock
Rating: 4.8181 (14 reviews)

SKU: 85407549658

4.8

EUR20.16 EUR42.16

Pay in 4 interest-free payments of $5.04 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 22 - Aug 27

Description

doi: 10.1016/S0140-6736(18)30485-9 237 MerkelSMogilevskajaNMengelMHallerHSchwarzA

How GLP-1s Lower Your Risk of Heart Disease It goes way beyond weight loss

Read clinical review

Based on clinical trial data, retatrutide produces greater average weight loss (28.7% at 68 weeks with 12mg) compared to tirzepatide (22.5% at 72 weeks with 15mg)